Wang Huanhuan, Wei Jinlong, Wang Bin, Meng Lingbin, Xin Ying, Dong Lihua, Jiang Xin
Department of Radiation Oncology, The First Hospital, Jilin University, Changchun, China.
Department of Internal Medicine, Florida Hospital, Orlando, FL, USA.
Cancer Med. 2020 Jan;9(1):204-214. doi: 10.1002/cam4.2712. Epub 2019 Nov 15.
To evaluate the association of human papilloma virus (HPV) infection with prognosis, specifically overall survival (OS) and disease-free survival (DFS), in laryngeal squamous cell carcinoma (LSCC) patients.
A systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. LSCC was confirmed on the basis of histopathology, whereas HPV status was confirmed by polymerase chain reaction.
A total of 6539 articles were initially searched from 8 databases, of which 11 studies were eligible for our review. A total of 1442 LSCC cases were included in this analysis. Eight studies examined 3-year OS for LSCC. The pooled hazard ratio (HR) from the 8 studies was 0.29 (95% CI: 0.25-0.33). There was a statistically significant difference in 3-year OS between the HPV-negative and -positive groups, with the latter having a better survival. There was no statistically significant differences in 5- and 10-year OS. Five studies examined 3- and 5-year DFS for LSCC, whereas only 3 studies examined 10-year DFS. There was no statistically significant difference in 3-, 5-, and 10-year DFS between the HPV groups.
This study evaluated the survival impact of HPV infection in LSCC patients. The OS of the HPV-positive group was better than that of the HPV-negative group in terms of short-term survival. Compared with the HPV-negative group, the HPV-positive group had a better trend of DFS, suggesting that a larger sample size and further exploration of the pathology and local control of HPV-positive tumors are needed.
评估人乳头瘤病毒(HPV)感染与喉鳞状细胞癌(LSCC)患者预后的相关性,特别是总生存期(OS)和无病生存期(DFS)。
根据系统评价和Meta分析的首选报告项目(PRISMA)指南进行系统评价和Meta分析。LSCC通过组织病理学确诊,而HPV状态通过聚合酶链反应确认。
最初从8个数据库中检索到6539篇文章,其中11项研究符合我们的综述要求。本分析共纳入1442例LSCC病例。8项研究考察了LSCC的3年总生存期。这8项研究汇总的风险比(HR)为0.29(95%CI:0.25-0.33)。HPV阴性和阳性组的3年总生存期存在统计学显著差异,后者生存期更好。5年和10年总生存期无统计学显著差异。5项研究考察了LSCC的3年和5年无病生存期,而只有3项研究考察了10年无病生存期。HPV组之间的3年、5年和10年无病生存期无统计学显著差异。
本研究评估了HPV感染对LSCC患者生存的影响。在短期生存方面,HPV阳性组的总生存期优于HPV阴性组。与HPV阴性组相比,HPV阳性组的无病生存期有更好的趋势,提示需要更大样本量以及对HPV阳性肿瘤的病理学和局部控制进行进一步探索。